Received Sep 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 9C295 | IM / LL |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | EK7DG | IM / RL |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | 3 | MF0146 | IM / LL |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 3 | 2124039 | PO / MO |
lot EK7DG was given, this is the 1-Vial Menveo formulation that is only licensed for ages 10-55 yrs. o This infant should have received the 2-vial menveo formulation, this is licensed for ages 2mo-55 years ((Within ADVOCATE and VFC we use this formulation for ages 2mo 9 yrs.)